FDA Inspection 1174620 — Esperion
The FDA completed an inspection of Esperion on Jun 29, 2022 in Ann Arbor, MI. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 29, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Ann Arbor, MI (United States)
Additional details
Postmarket Adverse Drug Experience (PADE)